Anaplastic lymphoma kinase (ALK) rearrangements are driver mutations that occur in approximately 3%–7% of non-small cell lung cancer (NSCLC) cases, primarily in the lung adenocarcinoma subtype (Qin and Gadgeel, 2017; Smolarz et al., 2025). The gene discussed is ALK; the disease is lung adenocarcinoma.